NO20050935L - BMP-2 ostrogen-responsivt element og fremgangsmater for anvendelse av samme - Google Patents

BMP-2 ostrogen-responsivt element og fremgangsmater for anvendelse av samme

Info

Publication number
NO20050935L
NO20050935L NO20050935A NO20050935A NO20050935L NO 20050935 L NO20050935 L NO 20050935L NO 20050935 A NO20050935 A NO 20050935A NO 20050935 A NO20050935 A NO 20050935A NO 20050935 L NO20050935 L NO 20050935L
Authority
NO
Norway
Prior art keywords
estrogen
bmp
same
responsive element
methods
Prior art date
Application number
NO20050935A
Other languages
English (en)
Norwegian (no)
Inventor
Peter Van Nest Bodine
Dan Gazit
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20050935L publication Critical patent/NO20050935L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20050935A 2002-08-16 2005-02-21 BMP-2 ostrogen-responsivt element og fremgangsmater for anvendelse av samme NO20050935L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40402402P 2002-08-16 2002-08-16
PCT/US2003/023271 WO2004016639A1 (en) 2002-08-16 2003-08-18 Bmp-2 estrogen responsive element and methods of using the same

Publications (1)

Publication Number Publication Date
NO20050935L true NO20050935L (no) 2005-05-10

Family

ID=31888312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050935A NO20050935L (no) 2002-08-16 2005-02-21 BMP-2 ostrogen-responsivt element og fremgangsmater for anvendelse av samme

Country Status (14)

Country Link
US (1) US20050271637A1 (zh)
EP (1) EP1534731A4 (zh)
JP (1) JP2006500925A (zh)
KR (1) KR20050083635A (zh)
CN (1) CN1753904A (zh)
AU (1) AU2003261246A1 (zh)
BR (1) BR0313729A (zh)
CA (1) CA2497304A1 (zh)
CO (1) CO5721011A2 (zh)
MX (1) MXPA05001694A (zh)
NO (1) NO20050935L (zh)
RU (1) RU2005107330A (zh)
WO (1) WO2004016639A1 (zh)
ZA (1) ZA200502131B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
KR20190097310A (ko) 2005-11-23 2019-08-20 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN103920139B (zh) 2007-02-01 2018-02-02 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI459963B (zh) 2007-02-09 2014-11-11 Acceleron Pharma Inc 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (da) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf-fanger til anvendelse ved behandling af anæmi
EP3058986B1 (en) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SI3227675T1 (sl) 2014-12-03 2023-07-31 Celgene Corporation Antagonisti aktivin-actrii in uporaba za zdravljenje mielodisplastičnega sindroma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
JPS59500735A (ja) * 1983-04-18 1984-04-26 エス・ア−ル・アイ・インタ−ナシヨナル 人間の癌診断のための方法および試験キツト
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
WO1998025460A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
JPH11313673A (ja) * 1998-04-30 1999-11-16 Hoechst Marion Roussel Kk ヒトbmp−2プロモーターおよびこれを用いた骨関連物質の探索法
US6630304B1 (en) * 2000-09-14 2003-10-07 Decode Genetics Ehf. Human osteoporosis gene

Also Published As

Publication number Publication date
EP1534731A1 (en) 2005-06-01
CO5721011A2 (es) 2007-01-31
BR0313729A (pt) 2005-06-21
JP2006500925A (ja) 2006-01-12
KR20050083635A (ko) 2005-08-26
ZA200502131B (en) 2005-09-21
AU2003261246A1 (en) 2004-03-03
US20050271637A1 (en) 2005-12-08
WO2004016639A1 (en) 2004-02-26
EP1534731A4 (en) 2006-05-17
RU2005107330A (ru) 2005-10-10
MXPA05001694A (es) 2005-07-22
CA2497304A1 (en) 2004-02-26
CN1753904A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
NO20050935L (no) BMP-2 ostrogen-responsivt element og fremgangsmater for anvendelse av samme
Bellare et al. A role for ubiquitin in the spliceosome assembly pathway
Giangrande et al. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene.
Ohsato et al. Mammalian mitochondrial endonuclease G: Digestion of R‐loops and localization in intermembrane space
WO2001012662A3 (en) Membrane associated proteins
BRPI0514805A (pt) sistema e processo para transformar o estilo de uma mensagem
BRPI0511906A (pt) isolamento de proteìnas do plasma ou soro
WO1999036550A3 (en) Human protease molecules
DE60322880D1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
NO20070067L (no) Pyrrolopyridinderivater
Chong et al. Pivotal role for the ubiquitin Y59-E51 loop in lysine 48 polyubiquitination
ATE488591T1 (de) Neuer l-lysin-induzierbarer promotor
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
DK1141358T3 (da) Stabilt transfekterede celler til identificering af forbindelser, der påvirker stabiliteten af mRNA
WO2000026245A3 (en) Human membrane transport proteins
WO2000005374A3 (en) Molecules associated with cell proliferation
NO20024048D0 (no) Fremgangsmåte for drift av en elektrolysecelle samt midler for samme
NO20022711L (no) Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
WO2004044165A3 (en) Lipid-associated proteins
WO1999041373A3 (en) Human transport-associated molecules
WO2000078954A3 (en) Human transcriptional regulator proteins
WO2003077875A3 (en) Proteins associated with growth, differentiation, and death
WO2002002757A3 (en) Adenylyl and guanylyl cyclases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application